scholarly journals Higher preoperative serum levels of PD ‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF ‐targeted therapy and unfavorable prognosis of renal cell carcinoma

2016 ◽  
Vol 5 (8) ◽  
pp. 1810-1820 ◽  
Author(s):  
Takehiko Fukuda ◽  
Takao Kamai ◽  
Akinori Masuda ◽  
Akinori Nukui ◽  
Hideyuki Abe ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Poor Response ◽  
Metastatic Potential ◽  
Serum Levels ◽  
Preoperative Serum

scholarly journals Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms

Kidney Cancer ◽  
2021 ◽  
pp. 1-13
Author(s):  
Nellowe Candelario ◽  
Christopher Geiger ◽  
Thomas Flaig
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Poor Response ◽  
Future Research ◽  
Sarcomatoid Renal Cell Carcinoma ◽  
Post Hoc

Sarcomatoid renal cell carcinoma (sRCC) is an aggressive form of kidney cancer that is associated with poor prognosis. It can arise from any histologic type of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic therapy. Nephrectomy is the treatment of choice in locally resectable disease. The therapeutic options for sRCC have evolved in the past decade. Cytotoxic chemotherapy and monotherapy with targeted therapy (VEGF and mTOR) have historically shown poor response rates and survival in the treatment of metastatic sRCC. The use of checkpoint inhibitors and their combination with targeted therapy against VEGF has changed the landscape and outcomes for renal cell carcinoma. Given the rarity of sRCC most of the data on treatment is from small cohorts or extrapolation from larger clinical trials. The benefit from the combination of checkpoint inhibitors and targeted therapy to VEGF has shown promise in the sRCC population in post hoc analysis of large clinical trials. Future research focusing on further characterizing the unique biologic and clinical features of sRCC is critical in advancing the knowledge and developing effective therapy to improve clinical outcomes and survival.

Rare localization of renal cell carcinoma metastases in the paranasal sinuses and breast: a case report

2019 ◽  
Vol 22 (6) ◽  
pp. 13-22
Author(s):  
E. V. Kryaneva ◽  
N. A. Rubtsova ◽  
A. V. Levshakova ◽  
A. I. Khalimon ◽  
A. V. Leontyev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paranasal Sinuses ◽  
Renal Cell ◽  
Clinical Case ◽  
Clear Cell ◽  
Malignant Tumors ◽  
Metastatic Potential ◽  
Cell Renal Cell Carcinoma ◽  
Metastatic Lesions

This article presents a clinical case demonsratinga high metastatic potential of clear cell renal cell carcinoma combined with atypical metastases to breast and paranasal sinuses. The prevalence of metastatic lesions to the breast and paranasal sinuses in various malignant tumors depending on their morphological forms is analyzed. The authors present an analysis of data published for the last 30 years. The optimal diagnostic algorithms to detect the progression of renal cell carcinoma and to evaluate the effectiveness of the treatment are considered.

Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma

2018 ◽  
Vol 25 (6) ◽  
pp. 528-533
Author(s):  
Dehua Liao ◽  
Dangang Shangguan ◽  
Dunwu Yao ◽  
Qing Zhu ◽  
Lizhi Cao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Therapeutic Drug Monitoring ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Drug Monitoring ◽  
Renal Cell ◽  
Therapeutic Drug

Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era

2021 ◽  
Author(s):  
Sei Naito ◽  
Tomoyuki Kato ◽  
Kazuyuki Numakura ◽  
Shingo Hatakeyama ◽  
Tomoyuki Koguchi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

1658 METASTASECTOMY FOLLOWING TARGETED THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Jose Karam ◽  
Leticia Varella ◽  
Jorge Garcia ◽  
Robert Dreicer ◽  
Steven Campbell ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document